Phenomix Sciences

Phenomix Sciences is a privately-held, AI-driven diagnostics company founded in 2018 and headquartered in Minneapolis, MN. The company operates at the intersection of diagnostics, genetics, and AI, focusing on the massive and growing obesity market. Its core value proposition is addressing the high variability in patient response to new obesity medications like GLP-1s by using a proprietary platform to identify patient phenotypes and match them to the most effective therapeutic pathways. By moving away from trial-and-error, Phenomix aims to improve clinical outcomes, patient compliance, and reduce overall healthcare costs.

AI-enabled platform that integrates genetic, clinical, and biomarker data to map biological pathways driving obesity and predict patient response to different therapeutic interventions.

The competitive landscape is emerging. Phenomix is an early mover in AI-driven obesity phenotyping. Potential competitors include other specialty diagnostic startups, large clinical labs expanding into complex disease analysis, and pharmaceutical companies that may develop companion diagnostics for their own obesity drugs.